Navigation Links
Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Date:7/19/2010

MONTREAL and HONG KONG, China, July 19 /PRNewswire/ - Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).

This study, entitled "A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination with Sorafenib in Patients With Advanced Hepatocellular Carcinoma", is being conducted exclusively in Hong Kong.

The interim data, derived from the analysis of the 13 patients treated in the Phase 1 portion of this trial indicates that AEG35156 not only appears to be well tolerated when given in combination with sorafenib but may also prolong progression-free and overall survival when compared to historical data where patients were treated with sorafenib alone. Indeed, median progression-free survival of the Phase 1 patients was about 4 months and overall survival about 10 months. This data compares favorably with the median progression-free survival of 2.8 months and overall survival of 6.5 months noted in the sorafenib Phase 3 registration trial performed in the Asia Pacific region in a similar patient population.

"I am greatly encouraged by this interim data read and look forward to completing this study as quickly as possible to ascertain whether the improved survival data can be confirmed in the Phase 2 portion of the trial." declared Dr. Jacques Jolivet, Senior Vice-President, Clinical of the trial's sponsor, Aegera Therapeutics.

"We are excited about the results of the Phase I por
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
3. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
4. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
5. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... H. "Pete" Petit, has been awarded the Lifetime Achievement ... Southeast Program. The Entrepreneur Of The ...
(Date:6/29/2015)... ... June 29, 2015 , ... The StampedeCon 2015 Big ... the fourth year in a row, will bring top technology professionals to St. Louis. ... the intersection of data and technology. The event is proudly sponsored by DataStax, Cisco, ...
(Date:6/29/2015)... 29, 2015 Elsevier , ... products and services, today announced the highlights of its ... 2014 Journal Citation Reports® (JCR) published by Thomson Reuters, ... from 2013 to 2014, ahead of the aggregate across ... rank in 62 subject categories, up from 61 in ...
(Date:6/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... all nominees listed in the management information circular ... 2015 Annual Meeting of Shareholders, held earlier today, ... the following 5 nominees proposed by management were ... until the Company,s next Annual Meeting of Shareholders ...
Breaking Biology Technology:EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... CA -- Science fiction fans still have another two months ... of actual science can feast their eyes now on the ... of a graphene crystal. Given that graphene single-layered sheets ... the key to the future of the electronics industry, the ...
... N.C., March 31 Cornerstone Therapeutics Inc. (Nasdaq: ... acquiring, developing and commercializing significant products primarily for the ... and Chief Executive Officer, will be presenting a corporate ... Biotech Industry Conference at 2:00 PM EDT on Thursday, ...
... Joint Venture to be funded by Cadila Pharmaceuticals ... $11 Million Capital Investment in Novavax , ROCKVILLE, ... NVAX ) announced today it has formed ... India) to develop, manufacture and market vaccines, pharmaceuticals ...
Cached Biology Technology:Spring 'blockbuster' movie now showing 2Spring 'blockbuster' movie now showing 3Spring 'blockbuster' movie now showing 4Spring 'blockbuster' movie now showing 5Cornerstone Therapeutics to Present at BioCentury's 2009 Future Leaders in the Biotech Industry Conference 2Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 2Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 3Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 4Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 5Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India 6
(Date:6/24/2015)... 2015 Research and ... the "Huawei Ascend Mate 7 Fingerprint Sensor ... offering. Huawei,s technological choice for the ... than Apple,s and Samsung,s one. The Ascend Mate ... Fingerprint Cards, a main actor in capacitive sensing ...
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
(Date:6/17/2015)... , June 17, 2015  Synaptics Inc. ... interface solutions, today announced that Xiaomi, one of ... Synaptics ® ClearPad ® family of ... driver integrated circuits (DDICs) for its latest smartphones, ... leveraging ClearPad for full in-cell display solutions and ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... St. Michael,s hospital have identified 29 proteins that are ... cancer. The discovery will help physicians recognize which tumours ... patients with more intensive treatment and closer followup., "Metastatic ... malignancies and patients have dismal prognosis," said Dr. George ...
... New research that relied in part on satellite images suggests ... the 1800s, is one cause for the larger, hotter and ... of the American West. The arid region covers about 230,000 ... of Utah, Colorado, Idaho, California and Oregon. Bethany Bradley, ...
... fine arts and the exact sciences may appear an ... both. Prof. Karen Avraham and PhD candidate Shaked Shivatzki ... this truth when creating Hearing and Deafness: Structure and ... of Human Genetics art competition. Their work was awarded ...
Cached Biology News:Tracking invasive cheatgrass role in larger, more frequent Western fires 2Tracking invasive cheatgrass role in larger, more frequent Western fires 3Embracing the art of science 2
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... service, ExonHit can design custom microarrays to ... gene list. Proprietary algorithms are used ... probes from high quality, spliced cDNAs aligned ... contained in a custom SpliceArray is profiled ...
... Visualizer DX's sensitivity of DNA detection has been ... in an agarose gel can be detected > ... can be purified by organic solvent extraction or ... kits worked well.) DNA excised from agarose ...
... SPE Workstation is a modular, highly scalable, ... Utilizing 1ml or 3ml industry standard SPE ... 100 samples in less than two hours ... 10 cartridges, and up to 10 modules ...
Biology Products: